Business

Neurovascular Embolization Devices Market to Register CAGR 4.4% Growth in Revenue During the Forecast Period 2028

The increasing awareness regarding neurovascular disease, and technological advancements in the diagnostic techniques are expected to propel the demand for neurovascular embolization devices over the forecast period.

As per the latest research by the company, theglobal neurovascular embolization devices marketis expected to account for more thanUS$ 1,733.1 Mn, in terms of value, by 2028 end. The report on neurovascular embolization devices market further projects significant growth potential with average year-on-year growth rate estimated at 4.4% through 2028.

Get Sample Copy of Report @https://www.persistencemarketresearch.com/samples/25969

Company Profile

  • Medtronic plc
  • Stryker Corporation
  • Terumo Corporation
  • Johnson & Johnson Services, Inc.
  • Penumbra Inc.
  • Balt Extrusion S.A
  • B. Braun Melsungen AG.
  • Integra LifeSciences Corporation
  • Resonetics Llc
  • Acandis GmbH
  • Others.

It is claimed by the Brain Aneurysm Foundation that around 6 million people in the U.S. suffer from brain aneurysms, which is expected to fuel the adoption minimally invasive neurovascular procedure. More than 500,000 people worldwide die due to stroke and other disorders associated with cerebral aneurysms, which is also increasing the demand for neurovascular embolization devices.

Intracranial aneurysm is prevalent in individuals younger than 60 years, as half out of the total mortality rate due to brain aneurysms comprises share of young individuals below age 50. It is been found by the Brain Aneurysm Foundation that about 15% of individuals possessing aneurysms in the neurovascular tract are very likely to have more than one aneurysm.

This factor further increases the demand for neurovascular embolization devices from the individuals suffering from cerebral aneurysms. Neurovascular aneurysms if not treated can result in severe consequences of neurological defects and permanent impairment of cognitive functions in the absence of neurovascular embolization devices.

Get To Know Methodology of Report @https://www.persistencemarketresearch.com/methodology/25969

The observations of these outcomes from brain aneurysms is also projected to fuel the demand for neurovascular embolization devices over the forecast period.

Neurovascular embolization devices are majorly adopted by hospitals owing to the requirement of high-end technological devices for the purpose of visualization, navigation, precision and complex nature of the surgery. The outpatient centers segment is projected to grow at aCAGR of 4.8%over the forecast period due to increasing demand for minimally invasive surgeries.

With significant presence of key players and high healthcare expenditure, North America is projected to be the dominant regional market for neurovascular embolization devices over the forecast period. Asia Pacific neurovascular embolization devices market is projected to grow at aCAGR of 5.2%due to growing awareness regarding brain aneurysms and other neurovascular diseases as well as significant presence of key manufacturers.

The company has segmented the global neurovascular embolization devices market based on product type, end user and region.

In terms of revenue, the embolization devices product type segment of the neurovascular embolization devices market is expected to hold significant share and grow at a highCAGR of 4.9%in the global neurovascular embolization devices market over the forecast period.

Access Full Report @https://www.persistencemarketresearch.com/checkout/25969

Flow diversion stents segment in the neurovascular embolization devices market is also expected to grow at a significant CAGR owing to the low associated risks and their growing adoption by the end users. Aneurysm clips segment in the neurovascular embolization devices market is estimated to contribute 2.4% market share in the terms of revenue. These devices have witness significant decrease in demand due to invasive nature of the treatment.

Additionally, the hospital end-use segment in the neurovascular embolization devices market is predicted to exhibit growth by4.2% CAGRduring the forecast period.

However, outpatient Centres hold key growth opportunity due to emergence of minimally invasive treatment modalities such as embolization coils, liquid embolic systems. North America neurovascular embolization devices market is estimated to create an incremental opportunity of US$ 229.7 Mn between 2018 and 2028.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Molecular Diagnostics Market –

Molecular Diagnostics MarketSegmentation by Key Players – Novartis AG, Roche Diagnostics, QIAGEN, Siemens Healthcare, Abbott Laboratories, Inc., Gen-Probe, Inc. (Hologic Inc.), Cepheid, Inc., Beckman Coulter, Inc., Becton, Dickinson & Company, Myriad Genetics, Inc., and bioMerieux.

Next-Generation Sequencing Market –

Next Generation Sequencing MarketSegmented by(By Application – Whole-genome Sequencing ,Exome Sequencing,Targeted Resequencing,De Novo Sequencing,RNA Sequencing,ChIP Sequencing,Methyl Sequencing,Others);By Technology- Targeted Sequencing & Resequencing,Whole Genome Sequencing,Whole Exome Sequencing.

Ophthalmology devises Market –

Ophthalmology devises MarketSegmentation by Key Players – Abbott Medical Optics Inc., Carl Zeiss Meditec AG, Bausch & Lomb Inc., Essilor International S.A, Ziemer Ophthalmic Systems AG and Topcon Corporation.

Intravenous Iron Drugs Market –

Intravenous (IV) Iron Drugs MarketSegmentation by Key Players- Actavis, Inc., AMAG Pharmaceuticals, Inc., Galenica Ltd., Fresenius Medical Care AG & Co. KGaA, Vifor Pharma Ltd., American Regent, Inc., Luitpold Pharmaceuticals, Inc., Pharmacosmos A/S, Rockwell Medical Technologies, Inc., and Sanofi.

Syndromes Progressive Ataxia Weakness Disorders Market –

Treatments forSyndromes of Progressive Ataxia and Weakness Disorders MarketSegmentation by Key Players- Abbott Laboratories, Acorda Therapeutics Inc., American Regent Inc., Baxter International Inc., Biogen Idec., Bristol-Myers Squibb, Cadila Healthcare Ltd., Eli Lilly and Company, Glaxosmilthkline Plc., Sanofi, Roche Holding Ltd., Pfizer Inc. and Novartis AG.

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMR’s collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

305 Broadway, 7th Floor
New York City, NY 10007
United States
Ph.no. +1-646-568-7751
E-mail id-sales@persistencemarketresearch.com
Website:https://www.persistencemarketresearch.com

Tags: , , , , , , , ,

See Campaign: http://www.persistencemarketresearch.com/market-research/neurovascular-embolization-devices-market.a
Contact Information:

305 Broadway, 7th Floor
New York City, NY 10007
United States
Ph.no. +1-646-568-7751
E-mail id- sales@persistencemarketresearch.com
Website: https://www.persistencemarketresearch.com

Tags:
, Extended Distribution, Research Newswire, English

Contact Information:

305 Broadway, 7th Floor
New York City, NY 10007
United States
Ph.no. +1-646-568-7751
E-mail id- sales@persistencemarketresearch.com
Website: https://www.persistencemarketresearch.com